Compare BEAT & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BEAT | ATNM |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.7M | 31.7M |
| IPO Year | 2021 | 2013 |
| Metric | BEAT | ATNM |
|---|---|---|
| Price | $0.42 | $1.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $5.63 | $4.50 |
| AVG Volume (30 Days) | ★ 299.1K | 161.7K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.07 | 14.17 |
| EPS | N/A | ★ 0.71 |
| Revenue | N/A | ★ $90,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $315.97 | N/A |
| P/E Ratio | ★ N/A | $1.97 |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $0.39 | $0.74 |
| 52 Week High | $4.00 | $1.74 |
| Indicator | BEAT | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 32.38 | 66.29 |
| Support Level | N/A | $0.96 |
| Resistance Level | $0.52 | $1.38 |
| Average True Range (ATR) | 0.03 | 0.08 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 15.18 | 73.33 |
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.